Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products

Cellular Immunology

Volumn 295, Issue 2, 2015, Pages 118-126

  Yin, Liusong ^a   Chen, Xiaoying ^a   Vicini, Paolo ^a   Rup, Bonita ^a   Hickling, Timothy P ^a  

^a PFIZER INC   (United States)

Author keywords

Efficacy; Immunogenicity; Prediction; Risk assessment; Safety; Therapeutic protein

Indexed keywords

PROTEIN DERIVATIVE; THERAPEUTIC PROTEIN PRODUCT; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; AUTOIMMUNE DISEASES; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; AUTOIMMUNE DISEASES; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84927514713     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.03.002     Document Type: Review

References (143)

1. Dimitrov D.S. Therapeutic proteins. Methods Mol. Biol. 2012, 899:1-26.
2. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 28:917-924.
3. Walsh G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 2014, 32:992-1000.
4. Barbosa M.D. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discovery Today 2011, 16:345-353.
5. Barbosa M.D., Kumar S., Loughrey H., Singh S.K. Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics. Drug Discovery Today 2012, 17:1282-1288.
6. Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis 2013, 5:561-574.
7. Moss A.C., Brinks V., Carpenter J.F. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment. Pharmacol. Ther. 2013, 38:1188-1197.
8. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD) a meta-analysis. Am. J. Gastroenterol. 2013, 108:40-47. quiz 48.
9. van Schouwenburg P.A., Rispens T., Wolbink G.J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 2013, 9:164-172.
10. Baert F., Noman M., Vermeire S., Van Assche G., D.H'aens G., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003, 348:601-608.
11. Pascual-Salcedo D., Plasencia C., Ramiro S., Nuno L., Bonilla G., Nagore D., Ruiz Del Agua A., Martinez A., Aarden L., Martin-Mola E., Balsa A. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011, 50:1445-1452.
12. Bray G.L., Gomperts E.D., Courter S., Gruppo R., Gordon E.M., Manco-Johnson M., Shapiro A., Scheibel E., White G., Lee M. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994, 83:2428-2435.
13. Antonelli G. Neutralising antibodies against interferon beta in multiple sclerosis. Lancet 2004, 363:168. author reply 168-169.
14. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., Teoh L.A., Fischkoff S.A., Chartash E.K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48:35-45.
15. Weisman M.H., Moreland L.W., Furst D.E., Weinblatt M.E., Keystone E.C., Paulus H.E., Teoh L.S., Velagapudi R.B., Noertersheuser P.A., Granneman G.R., Fischkoff S.A., Chartash E.K. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin. Ther. 2003, 25:1700-1721.
16. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., Dijkmans B.A., Aarden L., Wolbink G.J. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
17. Jamnitski A., Bartelds G.M., Nurmohamed M.T., van Schouwenburg P.A., van Schaardenburg D., Stapel S.O., Dijkmans B.A., Aarden L., Wolbink G.J. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann. Rheum. Dis. 2011, 70:284-288.
18. Shankar G., Arkin S., Cocea L., Devanarayan V., Kirshner S., Kromminga A., Quarmby V., Richards S., Schneider C.K., Subramanyam M., Swanson S., Verthelyi D., Yim S. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014, 16:658-673.
19. Bertolotto A., Malucchi S., Sala A., Orefice G., Carrieri P.B., Capobianco M., Milano E., Melis F., Giordana M.T. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J. Neurol. Neurosurg. Psychiatry 2002, 73:148-153.
20. Bertolotto A., Sala A., Malucchi S., Marnetto F., Caldano M., Di Sapio A., Capobianco M., Gilli F. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J. Neurol. Neurosurg. Psychiatry 2004, 75:1294-1299.
21. Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., Green J., Gupta S., Herzyk D., Hurst C., Ivens I.A., Kawabata T., Maier C., Mounho B., Rup B., Shankar G., Smith H., Thomas P., Wierda D. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol.: RTP 2009, 54:164-182.
22. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006, 54:3782-3789.
23. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de Groot E., Nurmohamed M.T., Stapel S., Tak P.P., Aarden L., Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54:711-715.
24. Svenson M., Geborek P., Saxne T., Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007, 46:1828-1834.
25. Krieckaert C., Rispens T., Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr. Opin. Rheumatol. 2012, 24:306-311.
26. Benucci M., Saviola G., Meacci F., Manfredi M., Infantino M., Campi P., Severino M., Iorno M., Sarzi-Puttini P., Atzeni F. No correlations between the development of specific IgA and IgM antibodies against anti-TNF blocking agents, disease activity and adverse side reactions in patients with rheumatoid arthritis. Open Rheumatol. J. 2013, 7:75-80.
27. Maneiro J.R., Salgado E., Gomez-Reino J.J. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern. Med. 2013, 173:1416-1428.
28. Solomon G. Immunogenicity - implications for rheumatoid arthritis treatment. Bull. Hospital Joint Dis. 2013, 71:200-203.
29. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002, 346:469-475.
30. Bennett C.L., Luminari S., Nissenson A.R., Tallman M.S., Klinge S.A., McWilliams N., McKoy J.M., Kim B., Lyons E.A., Trifilio S.M., Raisch D.W., Evens A.M., Kuzel T.M., Schumock G.T., Belknap S.M., Locatelli F., Rossert J., Casadevall N. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 2004, 351:1403-1408.
31. Macdougall I.C. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol. Dial. Transplant. 2005, 20(Suppl. 4):iv9-iv15.
32. Yang J., Joo K.W., Kim Y.S., Ahn C., Han J.S., Kim S., Lee J.S. Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies. J. Nephrol. 2005, 18:102-105.
33. McKoy J.M., Stonecash R.E., Cournoyer D., Rossert J., Nissenson A.R., Raisch D.W., Casadevall N., Bennett C.L. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008, 48:1754-1762.
34. Peerlinck K., Arnout J., Gilles J.G., Saint-Remy J.M., Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb. Haemost. 1993, 69:115-118.
35. Rosendaal F.R., Nieuwenhuis H.K., van den Berg H.M., Heijboer H., Mauser-Bunschoten E.P., van der Meer J., Smit C., Strengers P.F., Briet E. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993, 81:2180-2186.
36. Peerlinck K., Arnout J., Di Giambattista M., Gilles J.G., Laub R., Jacquemin M., Saint-Remy J.M., Vermylen J. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb. Haemost. 1997, 77:80-86.
37. Corona T., Leon C., Ostrosky-Zeichner L. Severe anaphylaxis with recombinant interferon beta. Neurology 1999, 52:425.
38. Warrier I., Ewenstein B.M., Koerper M.A., Shapiro A., Key N., DiMichele D., Miller R.T., Pasi J., Rivard G.E., Sommer S.S., Katz J., Bergmann F., Ljung R., Petrini P., Lusher J.M. Factor IX inhibitors and anaphylaxis in hemophilia B. J. Pediatr. Hematol. Oncol. 1997, 19:23-27.
39. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., Kuter D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
40. Weber G., Gross J., Kromminga A., Loew H.H., Eckardt K.U. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J. Am. Soc. Nephrol.: JASN 2002, 13:2381-2383.
41. Finkelman F.D. Anaphylaxis lessons from mouse models. J. Allergy Clin. Immunol. 2007, 120:506-515. quiz 516-507.
42. Vultaggio A., Maggi E., Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr. Opin. Allergy Clin. Immunol. 2011, 11:262-268.
43. Purcell R.T., Lockey R.F. Immunologic responses to therapeutic biologic agents. J. Investig. Allergol. Clin. Immunol. 2008, 18:335-342.
44. Conrad D.H., Gibb D.R., Sturgill J. Regulation of the IgE response. Biol. Rep. 2010, 2.
45. Stubenrauch K., Wessels U., Birnboeck H., Ramirez F., Jahreis A., Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin. Ther. 2010, 32:1597-1609.
46. Vultaggio A., Matucci A., Nencini F., Pratesi S., Parronchi P., Rossi O., Romagnani S., Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010, 65:657-661.
47. Minuk G.Y., Hoofnagle J.H., McAuliffe V.J., Purcell R.H. IgM antibody responses to hepatitis B surface antigen in recipients of hepatitis B virus vaccine. J. Infect. Dis. 1983, 148:330.
48. Richard J., Prang N. The formulation and immunogenicity of therapeutic proteins product quality as a key factor. IDrugs Invest. Drugs J. 2010, 13:550-558.
49. De Groot A.S., Scott D.W. Immunogenicity of protein therapeutics. Trends Immunol. 2007, 28:482-490.
50. Vos Q., Lees A., Wu Z.Q., Snapper C.M., Mond J.J. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 2000, 176:154-170.
51. Kumar S., Singh S.K., Wang X., Rup B., Gill D. Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions. Pharm. Res. 2011, 28:949-961.
52. Sethu S., Govindappa K., Alhaidari M., Pirmohamed M., Park K., Sathish J. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch. Immunol. Ther. Exp. 2012, 60:331-344.
53. Snapper C.M., McIntyre T.M., Mandler R., Pecanha L.M., Finkelman F.D., Lees A., Mond J.J. Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J. Exp. Med. 1992, 175:1367-1371.
54. Guinamard R., Okigaki M., Schlessinger J., Ravetch J.V. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat. Immunol. 2000, 1:31-36.
55. Puga I., Cols M., Barra C.M., He B., Cassis L., Gentile M., Comerma L., Chorny A., Shan M., Xu W., Magri G., Knowles D.M., Tam W., Chiu A., Bussel J.B., Serrano S., Lorente J.A., Bellosillo B., Lloreta J., Juanpere N., Alameda F., Baro T., de Heredia C.D., Toran N., Catala A., Torrebadell M., Fortuny C., Cusi V., Carreras C., Diaz G.A., Blander J.M., Farber C.M., Silvestri G., Cunningham-Rundles C., Calvillo M., Dufour C., Notarangelo L.D., Lougaris V., Plebani A., Casanova J.L., Ganal S.C., Diefenbach A., Arostegui J.I., Juan M., Yague J., Mahlaoui N., Donadieu J., Chen K., Cerutti A. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat. Immunol. 2012, 13:170-180.
56. Verthelyi D., Wang V. Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins. PLoS ONE 2010, 5:e15252.
57. Singh S.K. Impact of product-related factors on immunogenicity of biotherapeutics. J. Pharm. Sci. 2011, 100:354-387.
58. Lacroix-Desmazes S., Navarrete A.M., Andre S., Bayry J., Kaveri S.V., Dasgupta S. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008, 112:240-249.
59. Hoffmann S., Cepok S., Grummel V., Lehmann-Horn K., Hackermuller J., Stadler P.F., Hartung H.P., Berthele A., Deisenhammer F., Wassmuth R., Hemmer B. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am. J. Hum. Genet. 2008, 83:219-227.
60. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Wolbink G.J., de Vries N., Tak P.P., Dijkmans B.A., Crusius J.B., van der Horst-Bruinsma I.E. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 2009, 60:2541-2542.
61. Astermark J. Prevention and prediction of inhibitor risk. Haemophilia 2012, 18(Suppl. 4):38-42.
62. Ragnhammar P., Friesen H.J., Frodin J.E., Lefvert A.K., Hassan M., Osterborg A., Mellstedt H. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 1994, 84:4078-4087.
63. van Schouwenburg P.A., Krieckaert C.L., Rispens T., Aarden L., Wolbink G.J., Wouters D. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann. Rheum. Dis. 2013, 72:1680-1686.
64. Xue L., Fiscella M., Rajadhyaksha M., Goyal J., Holland C., Gorovits B., Morimoto A. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists. AAPS J. 2013, 15:852-855.
65. Xue L., Rup B. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J. 2013, 15:893-896.
66. Konrad M.W., Childs A.L., Merigan T.C., Borden E.C. Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J. Clin. Immunol. 1987, 7:365-375.
67. Ross C., Clemmesen K.M., Svenson M., Sorensen P.S., Koch-Henriksen N., Skovgaard G.L., Bendtzen K. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration, Danish Multiple Sclerosis Study Group. Ann. Neurol. 2000, 48:706-712.
68. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 2005, 20(Suppl. 6):vi3-vi9.
69. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., Antoni C., Leeb B., Elliott M.J., Woody J.N., Schaible T.F., Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41:1552-1563.
70. Oldenburg J., Schwaab R., Brackmann H.H. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang. 1999, 77(Suppl. 1):49-54.
71. Reding M.T., Wu H., Krampf M., Okita D.K., Diethelm-Okita B.M., Key N.S., Conti-Fine B.M. CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb. Haemost. 1999, 82:509-515.
72. Reding M.T., Wu H., Krampf M., Okita D.K., Diethelm-Okita B.M., Christie B.A., Key N.S., Conti-Fine B.M. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb. Haemost. 2000, 84:643-652.
73. Franchini M., Capra F., Nicolini N., Veneri D., Manzato F., Baudo F., Lippi G. Drug-induced anti-factor VIII antibodies: a systematic review. Med. Sci. Monit. 2007, 13:RA55-RA61.
74. Baker M.P., Reynolds H.M., Lumicisi B., Bryson C.J. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self/nonself 2010, 1:314-322.
75. Grossberg S.E., Oger J., Grossberg L.D., Gehchan A., Klein J.P. Frequency and magnitude of interferon beta neutralizing antibodies in the evaluation of interferon beta immunogenicity in patients with multiple sclerosis. J. Interferon Cytokine Res. 2011, 31:337-344.
76. Chirino A.J., Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol. 2004, 22:1383-1391.
77. Carpenter J., Cherney B., Lubinecki A., Ma S., Marszal E., Mire-Sluis A., Nikolai T., Novak J., Ragheb J., Simak J. Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation. Biologicals 2010, 38:602-611.
78. Yeung V.P., Chang J., Miller J., Barnett C., Stickler M., Harding F.A. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 2004, 172:6658-6665.
79. Jones T.D., Phillips W.J., Smith B.J., Bamford C.A., Nayee P.D., Baglin T.P., Gaston J.S., Baker M.P. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J. Thromb. Haemostasis: JTH 2005, 3:991-1000.
80. Kosmac M., Avcin T., Toplak N., Simonini G., Cimaz R., Curin Serbec V. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatric Res. 2011, 69:243-248.
81. Joubert M.K., Luo Q., Nashed-Samuel Y., Wypych J., Narhi L.O. Classification and characterization of therapeutic antibody aggregates. J. Biol. Chem. 2011, 286:25118-25133.
82. Kumar S., Mitchell M.A., Rup B., Singh S.K. Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies. J. Pharm. Sci. 2012, 101:2686-2701.
83. Seidl A., Hainzl O., Richter M., Fischer R., Bohm S., Deutel B., Hartinger M., Windisch J., Casadevall N., London G.M., Macdougall I. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm. Res. 2012, 29:1454-1467.
84. Ratanji K.D., Derrick J.P., Dearman R.J., Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J. Immunotoxicol. 2014, 11:99-109.
85. Barnard J.G., Babcock K., Carpenter J.F. Characterization and quantitation of aggregates and particles in interferon-beta products: potential links between product quality attributes and immunogenicity. J. Pharm. Sci. 2013, 102:915-928.
86. Rombach-Riegraf V., Karle A.C., Wolf B., Sorde L., Koepke S., Gottlieb S., Krieg J., Djidja M.C., Baban A., Spindeldreher S., Koulov A.V., Kiessling A. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. PLoS ONE 2014, 9:e86322.
87. Hermeling S., Aranha L., Damen J.M., Slijper M., Schellekens H., Crommelin D.J., Jiskoot W. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm. Res. 2005, 22:1997-2006.
88. Hermeling S., Schellekens H., Maas C., Gebbink M.F., Crommelin D.J., Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm. Sci. 2006, 95:1084-1096.
89. Human P., Ilsley H., Roberson C., Grovender E., Van Antwerp B., Fogt E., Zilla P. Assessment of the immunogenicity of mechanically induced interferon aggregates in a transgenic mouse model. J. Pharmaceut. Sci. 2014.
90. Filipe V., Jiskoot W., Basmeleh A.H., Halim A., Schellekens H., Brinks V. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. mAbs 2012, 4:740-752.
91. Joubert M.K., Hokom M., Eakin C., Zhou L., Deshpande M., Baker M.P., Goletz T.J., Kerwin B.A., Chirmule N., Narhi L.O., Jawa V. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J. Biol. Chem. 2012, 287:25266-25279.
92. Freitag A.J., Shomali M., Michalakis S., Biel M., Siedler M., Kaymakcalan Z., Carpenter J.F., Randolph T.W., Winter G., Engert J. Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice. Pharm. Res. 2014.
93. Purohit V.S., Middaugh C.R., Balasubramanian S.V. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J. Pharm. Sci. 2006, 95:358-371.
94. Pisal D.S., Kosloski M.P., Middaugh C.R., Bankert R.B., Balu-Iyer S.V. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J. Pharm. Sci. 2012, 101:2055-2065.
95. van Beers M.M., Sauerborn M., Gilli F., Brinks V., Schellekens H., Jiskoot W. Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm. Res. 2010, 27:1812-1824.
96. Fradkin A.H., Carpenter J.F., Randolph T.W. Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J. Pharm. Sci. 2011, 100:4953-4964.
97. Jones J.C., Settles E.W., Brandt C.R., Schultz-Cherry S. Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine. Vaccine 2011, 29:7696-7703.
98. Ahmadi M., Bryson C.J., Cloake E.A., Welch K., Filipe V., Romeijn S., Hawe A., Jiskoot W., Baker M.P., Fogg M.H. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm. Res. 2014.
99. Braun A., Alsenz J. Development and use of enzyme-linked immunosorbent assays (ELISA) for the detection of protein aggregates in interferon-alpha (IFN-alpha) formulations. Pharm. Res. 1997, 14:1394-1400.
100. Skupsky J., Zhang A.H., Su Y., Scott D.W. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood 2009, 114:4741-4748.
101. Fathallah A.M., Bankert R.B., Balu-Iyer S.V. Immunogenicity of subcutaneously administered therapeutic proteins-a mechanistic perspective. AAPS J. 2013, 15:897-900.
102. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1-16.
103. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., Richards S.M., Rup B., Shores E., Swanson S.J., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 2007, 321:1-18.
104. Aarden L., Ruuls S.R., Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 2008, 20:431-435.
105. van Schouwenburg P.A., Bartelds G.M., Hart M.H., Aarden L., Wolbink G.J., Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J. Immunol. Methods 2010, 362:82-88.
106. Wang S.L., Ohrmund L., Hauenstein S., Salbato J., Reddy R., Monk P., Lockton S., Ling N., Singh S. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J. Immunol. Methods 2012, 382:177-188.
107. Lacroix-Desmazes S., Misra N., Bayry J., Artaud C., Drayton B., Kaveri S.V., Kazatchkine M.D. Pathophysiology of inhibitors to factor VIII in patients with haemophilia A. Haemophilia 2002, 8:273-279.
108. van Schouwenburg P.A., van de Stadt L.A., de Jong R.N., van Buren E.E., Kruithof S., de Groot E., Hart M., van Ham S.M., Rispens T., Aarden L., Wolbink G.J., Wouters D. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann. Rheum. Dis. 2013, 72:104-109.
109. Khanna R., Feagan B.G. Current and future status of therapeutic drug monitoring in the treatment of IBD. Curr. Treat. Options Gastroenterol. 2014, 12:76-89.
110. Scott F.I., Lichtenstein G.R. Therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Current Treat. Options in Gastroenterol. 2014, 12:59-75.
111. Steenholdt C., Bendtzen K., Brynskov J., Thomsen O.O., Ainsworth M.A. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am. J. Gastroenterol. 2014, 109:1055-1064.
112. Gorovits B., McNally J., Fiorotti C., Leung S. Protein-based matrix interferences in ligand-binding assays. Bioanalysis 2014, 6:1131-1140.
113. Messitt T.J., Terry F., Moise L., Martin W., De Groot A.S. A comparison of two methods for T cell epitope mapping: "cell free" in vitro versus immunoinformatics. Immun. Res. 2011, 7.
114. Yin L., Calvo-Calle J.M., Dominguez-Amorocho O., Stern L.J. HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives. J. Immunol. 2012, 189:3983-3994.
115. Jawa V., Cousens L.P., Awwad M., Wakshull E., Kropshofer H., De Groot A.S. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin. Immunol. 2013, 149:534-555.
116. Lundegaard C., Lund O., Kesmir C., Brunak S., Nielsen M. Modeling the adaptive immune system: predictions and simulations. Bioinformatics 2007, 23:3265-3275.
117. Brinks V., Weinbuch D., Baker M., Dean Y., Stas P., Kostense S., Rup B., Jiskoot W. Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm. Res. 2013, 30:1719-1728.
118. Nanda N.K., Sant A.J. DM determines the cryptic and immunodominant fate of T cell epitopes. J. Exp. Med. 2000, 192:781-788.
119. Sant A.J., Chaves F.A., Jenks S.A., Richards K.A., Menges P., Weaver J.M., Lazarski C.A. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II: peptide complexes. Immunol. Rev. 2005, 207:261-278.
120. Chen X., Hickling T., Kraynov E., Kuang B., Parng C., Vicini P. A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics. AAPS J. 2013, 15:1141-1154.
121. Chen X., Hickling T.P., Vicini P. A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications. CPT: Pharmacomet. Systems Pharmacol. 2014, 3:e134.
122. Chen X., Hickling T.P., Vicini P. A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model. CPT: Pharmacomet. Systems Pharmacol. 2014, 3:e133.
123. Gomez-Mantilla J.D., Troconiz I.F., Parra-Guillen Z., Garrido M.J. Review on modeling anti-antibody responses to monoclonal antibodies. J. Pharmacokinet Pharmacodyn. 2014, 41:523-536.
124. Moise L., Song C., Martin W.D., Tassone R., De Groot A.S., Scott D.W. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin. Immunol. 2012, 142:320-331.
125. Brinks V., Jiskoot W., Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm. Res. 2011, 28:2379-2385.
126. Koren E., De Groot A.S., Jawa V., Beck K.D., Boone T., Rivera D., Li L., Mytych D., Koscec M., Weeraratne D., Swanson S., Martin W. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 2007, 124:26-32.
127. Manoury B., Mazzeo D., Fugger L., Viner N., Ponsford M., Streeter H., Mazza G., Wraith D.C., Watts C. Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat. Immunol. 2002, 3:169-174.
128. Burster T., Beck A., Tolosa E., Marin-Esteban V., Rotzschke O., Falk K., Lautwein A., Reich M., Brandenburg J., Schwarz G., Wiendl H., Melms A., Lehmann R., Stevanovic S., Kalbacher H., Driessen C. Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes. J. Immunol. 2004, 172:5495-5503.
129. Liu G.Y., Fairchild P.J., Smith R.M., Prowle J.R., Kioussis D., Wraith D.C. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995, 3:407-415.
130. Harrington C.J., Paez A., Hunkapiller T., Mannikko V., Brabb T., Ahearn M., Beeson C., Goverman J. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 1998, 8:571-580.
131. Kedl R.M., Rees W.A., Hildeman D.A., Schaefer B., Mitchell T., Kappler J., Marrack P. T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 2000, 192:1105-1113.
132. Kedl R.M., Kappler J.W., Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr. Opin. Immunol. 2003, 15:120-127.
133. Muraro P.A., Vergelli M., Kalbus M., Banks D.E., Nagle J.W., Tranquill L.R., Nepom G.T., Biddison W.E., McFarland H.F., Martin R. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. J. Clin. Invest. 1997, 100:339-349.
134. Li Y., Huang Y., Lue J., Quandt J.A., Martin R., Mariuzza R.A. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J. 2005, 24:2968-2979.
135. Yin Y., Li Y., Kerzic M.C., Martin R., Mariuzza R.A. Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J. 2011, 30:1137-1148.
136. FDA, Guidance for industry immunogenicity assessment for therapeutic protein products, (2014).
137. EMA, Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins, (2007).
138. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discovery 2002, 1:457-462.
139. van Schouwenburg P.A., Kruithof S., Votsmeier C., van Schie K., Hart M.H., de Jong R.N., van Buren E.E., van Ham M., Aarden L., Wolbink G., Wouters D., Rispens T. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J. Biol. Chem. 2014, 289:34482-34488.
140. Sauerborn M., Brinks V., Jiskoot W., Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol. Sci. 2010, 31:53-59.
141. Blyuss K.B., Nicholson L.B. The role of tunable activation thresholds in the dynamics of autoimmunity. J. Theor. Biol. 2012, 308:45-55.
142. Chaparro M., Guerra I., Munoz-Linares P., Gisbert J.P. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2012, 35:971-986.
143. Steenholdt C., Ainsworth M.A., Tovey M., Klausen T.W., Thomsen O.O., Brynskov J., Bendtzen K. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther. Drug Monit. 2013, 35:530-538.